BR112013012587A2 - composição farmacêutica para administração nasal - Google Patents

composição farmacêutica para administração nasal

Info

Publication number
BR112013012587A2
BR112013012587A2 BR112013012587A BR112013012587A BR112013012587A2 BR 112013012587 A2 BR112013012587 A2 BR 112013012587A2 BR 112013012587 A BR112013012587 A BR 112013012587A BR 112013012587 A BR112013012587 A BR 112013012587A BR 112013012587 A2 BR112013012587 A2 BR 112013012587A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
nasal administration
irritation
agent
provides
Prior art date
Application number
BR112013012587A
Other languages
English (en)
Inventor
Byong-Sun Choi
Geun-Hyeog Lee
Jin-Ha Park
Jong-Hyeon Ryu
O Mi-Jin
Sang-Yong Lee
Original Assignee
Hanlim Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanlim Pharmaceutical Co Ltd filed Critical Hanlim Pharmaceutical Co Ltd
Publication of BR112013012587A2 publication Critical patent/BR112013012587A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

composição farmacêutica para administração nasal. a presente invenção proporciona uma composição farmacêutica para administração nasal compreendendo furoato de mometasona e cloridrato de azelastina, em que a composição farmacêutica compreende taumatina como agente para reduzir o amargor e irritação.
BR112013012587A 2010-11-29 2011-11-18 composição farmacêutica para administração nasal BR112013012587A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100119632A KR101261230B1 (ko) 2010-11-29 2010-11-29 모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물
PCT/KR2011/008826 WO2012074231A2 (ko) 2010-11-29 2011-11-18 모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물

Publications (1)

Publication Number Publication Date
BR112013012587A2 true BR112013012587A2 (pt) 2016-09-06

Family

ID=46172356

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012587A BR112013012587A2 (pt) 2010-11-29 2011-11-18 composição farmacêutica para administração nasal

Country Status (10)

Country Link
US (1) US8859531B2 (pt)
EP (1) EP2647380B1 (pt)
JP (1) JP5775597B2 (pt)
KR (1) KR101261230B1 (pt)
CN (1) CN103237550B (pt)
BR (1) BR112013012587A2 (pt)
HU (1) HUE028740T2 (pt)
RU (1) RU2563115C2 (pt)
UA (1) UA111343C2 (pt)
WO (1) WO2012074231A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9783529B2 (en) 2013-03-13 2017-10-10 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
MX367674B (es) * 2013-09-13 2019-08-30 Glenmark Specialty Sa Composición farmacéutica de dosis fija estable que comprende mometasona y olopatadina.
CN103736098A (zh) * 2013-12-27 2014-04-23 于运红 一种含有比拉斯汀及糠酸莫米松的鼻内给药用药物组合物
CA3002384C (en) * 2015-10-25 2021-02-16 Iview Therapeutics, Inc. Pharmaceutical formulations that form gel in situ
CN109288790A (zh) * 2017-07-25 2019-02-01 健乔信元医药生技股份有限公司 鼻用医药组合物及其制备方法
CN110869023B (zh) * 2017-09-02 2023-07-04 艾威药业公司 原位凝胶形成药物组合物及其在鼻窦疾病中的应用
CN107737105A (zh) * 2017-11-28 2018-02-27 贵州云峰药业有限公司 一种鼻腔用盐酸氮卓斯汀组合物喷雾剂及生产工艺
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US10898493B2 (en) 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
WO2022035388A1 (en) * 2020-08-14 2022-02-17 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. Pharmaceutical compositions comprising azelastine and relevant excipients
WO2022098319A1 (en) * 2020-11-09 2022-05-12 Pharmactive Ilac Sanayi Ve Ticarey A.S. Pharmaceutical compositions comprising azelastine, beclomethasone and relevant excipients
WO2023014361A1 (en) * 2021-08-05 2023-02-09 La Pharma Tech Inc. Novel pharmaceutical compositions and methods for treatment of psychiatric disorders
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders
WO2024079676A1 (en) * 2022-10-12 2024-04-18 Glenmark Specialty S.A. Novel nasal spray assembling process

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053678T3 (es) 1987-11-13 1994-08-01 Asta Medica Ag Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular.
JP3190441B2 (ja) * 1992-07-20 2001-07-23 エーザイ株式会社 塩酸アゼラスチンを含有する安定な製剤
AU6392496A (en) 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
KR100746753B1 (ko) 1998-08-28 2007-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 고미 등을 경감한 의약조성물
DE10058459A1 (de) * 2000-11-24 2002-06-06 Haarmann & Reimer Gmbh Rhinologica
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
PL2522365T3 (pl) * 2004-11-24 2017-05-31 Meda Pharmaceuticals Inc. Kompozycje zawierające azelastynę i sposoby ich zastosowania
EP1981476A2 (en) 2006-02-09 2008-10-22 Schering Corporation Pharmaceutical formulations
US20100099650A1 (en) 2006-10-10 2010-04-22 Knauer Kent A Nasal spray composition and method for treating rhinitis, sinusitis or both
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
JP2010138125A (ja) * 2008-12-12 2010-06-24 Kyukyu Yakuhin Kogyo Kk 速溶性ニコチン含有フィルム製剤

Also Published As

Publication number Publication date
RU2013124024A (ru) 2015-01-10
KR20120058029A (ko) 2012-06-07
RU2563115C2 (ru) 2015-09-20
EP2647380A2 (en) 2013-10-09
JP5775597B2 (ja) 2015-09-09
CN103237550B (zh) 2016-05-18
WO2012074231A2 (ko) 2012-06-07
EP2647380B1 (en) 2016-02-03
US20130252929A1 (en) 2013-09-26
EP2647380A4 (en) 2015-03-11
HUE028740T2 (en) 2016-12-28
UA111343C2 (uk) 2016-04-25
WO2012074231A3 (ko) 2012-07-19
CN103237550A (zh) 2013-08-07
US8859531B2 (en) 2014-10-14
KR101261230B1 (ko) 2013-05-07
JP2013543889A (ja) 2013-12-09

Similar Documents

Publication Publication Date Title
BR112013012587A2 (pt) composição farmacêutica para administração nasal
UY34359A (es) ?tratamiento de esclerosis múltiple con combinación de laquinimod e interferón-beta?.
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
RS62383B1 (sr) Stabilna farmaceutska kompozicija sa fiksnom dozom koja sadrži mometazon i olopatadin za nazalnu primenu
PH12015500730A1 (en) Inhibitors of histone demethylases
CR20110110A (es) Composicion farmaceutica
BR112018010671A8 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
BR112012002143A2 (pt) agentes terapêuticos para redução dos níveis de hormônio da paratieóide.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
CO2017002472A2 (es) Formulación de acetato de abiraterona
BR112013010102A2 (pt) microagulha, arranjo de microagulhas, dispositivo de microagulhas, e, método para administrar um agente medicinal
BRPI1007732A2 (pt) aparelho para administração de medicamentos para a administração de um aerossol incluindo um medicamento para um paciente, kit para a administração de um aerossol incluindo um medicamento para um paciente e método de administração de um aerossol incluindo um medicamento para um paciente
BR112015001521A2 (pt) previsão de resposta ao tratamento para inibidor jak/stat
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
BR112014020008A8 (pt) composição farmacêutica, uso da mesma, e, processo para a fabricação de uma formulação.
BR112013018781A2 (pt) composto derivado de piridona, e, composição farmacêutica
BR112013003064A2 (pt) agente profilático ou terapêutico para a esteato-hepatite não alcoólica
CR11439A (es) Composiciones para inhalacion comprendiendo acido montelukast y un inhibidor pde-4 o un corticosteroide inhalado

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]